Latest Regulatory News

Vulcan Steel Limited has explained the late filing of a director’s interest notice due to an administrative error and outlined steps to strengthen compliance. The company commits to enhanced reminders and board training to prevent future delays.

Pilot Energy has sold its option to lease a solar development site to Strike Energy, a move prompted by recent government policy changes excluding blue hydrogen from key tax incentives.

Volt Resources Limited has had its trading suspension lifted following the release of an announcement about a new equity funding transaction, signaling renewed market activity.

Volt Resources has locked in a $11.1 million equity investment from Unbounded Opportunities Fund to accelerate development of its Bunyu Graphite Project in Tanzania, aiming to boost production and cut costs.

Almonty Industries has priced an upsized US$112.5 million share offering to accelerate development of key tungsten and molybdenum projects, reinforcing its position amid tightening global supply chains.

Star Minerals has received mining approval for its Tumblegum South Gold Project, setting the stage for mining to commence in early 2026. With robust production targets and a key partnership in place, the project is poised to advance swiftly.

Critical Metals Corp has partnered with Romania's state-owned FPCU in a 50/50 joint venture, securing half of the Tanbreez rare earth concentrate and boosting European supply chain security.

Medallion Metals and IGO Limited have agreed to extend the deadline for completing the Forrestania Nickel Operation acquisition, allowing more time to meet key conditions and secure environmental approvals.

Mayne Pharma has rejected Cosette Pharmaceuticals’ notice to terminate their merger agreement, citing Cosette’s failure to meet obligations that led to regulatory approval issues. The dispute raises fresh uncertainty over the proposed acquisition’s future.

Orion Minerals has responded to an ASX price query following a recent uptick in its share price, confirming no undisclosed material information exists while highlighting ongoing financing talks with Glencore.

Memphasys Limited has restructured its leadership by eliminating the CEO role to back a direct-selling global commercialisation strategy for its Felix™ System, anticipating imminent CE Mark approval to enter the European IVF market.

LTR Pharma has received regulatory clearance from the Therapeutic Goods Administration to commence its Phase II clinical trial of SPONTAN, focusing on men aged 65 and over. Patient recruitment is set to begin early next year, aiming to address a key gap in erectile dysfunction treatment.